ORLANDO, Fla., Dec. 4, 2017 /PRNewswire/ -- BD (Becton,
Dickinson and Company) (NYSE: BDX), a leading global medical
technology company, today revealed several technology innovations
to further optimize the entire medication management process at
this year's American Society of Health-System Pharmacists (ASHP)
2017 Midyear Meeting.
In addition to the recent introduction of the BD
HealthSight™ platform for enterprise medication
management – which offers a unique combination of connective
technologies, analytics and expert services – BD unveiled new
capabilities that will help hospitals and health systems drive a
more efficient and connected medication management process. Through
the company's unique ability to integrate its leading technologies,
such as BD Pyxis™ dispensing and BD Alaris™
infusion solutions – with each other and with the hospital's EMR –
hospitals and health systems can now unlock additional value out of
their medication management system.
"Our goal in achieving high-reliability in medication management
starts with standardizing practice across the system and leveraging
our technology and data to support that practice," said
Debbie Simonson, Pharm.D, vice
president, Pharmacy Services at Ochsner Health System. "BD is
providing us with a system and infrastructure that our team can
utilize to optimize our practice."
Ranjeet Banerjee, worldwide
president of Medication Management Solutions for BD states, "Our
aim is to combine our products through technology, services and
analytics to make it easier for our customers to deliver safe and
efficient care to patients. This integration through the BD
HealthSight platform will deliver significant new value to support
our customers in meeting their goals in the areas of medication
safety, enterprise-wide inventory optimization and clinician
productivity."
Exclusively at the BD booth, conference-goers will receive a
comprehensive demonstration of the company's enhanced solutions
that are reinventing the entire medication management process,
including:
Enterprise-wide inventory optimization and
availability:
- BD HealthSight viewer is an integrated, web-based pharmacy
operations dashboard that combines critical data from BD Pyxis
dispensing and BD Alaris infusion systems into a single view for
pharmacy and nursing. This visibility improves medication
availability and efficiency by enabling pharmacy to monitor device
and continuous infusion status and proactively respond to needs
such as stock-outs and dose requests before they impact nursing and
ultimately patients.
- The latest BD Pyxis™ ES software release works with BD
HealthSight analytics to enable bi-directional inventory and par
level management, helping improve efficiency and ensure
availability of medications needed for patient care.
- BD HealthSight analytics and comparative benchmarks coupled
with practice improvement services enable hospitals to monitor and
proactively address medication inventory needs, reduce waste and
provide recommendations for practice improvement.
Improved clinician productivity:
- The latest software release of the BD Pyxis ES system
introduces a variety of powerful benefits designed to increase
clinician productivity and time spent with patients. In addition to
bidirectional inventory level management, the release supports
interoperability with both Epic™ and Cerner™
enhanced dispensing as well as the ability to request needed
medications from the patient bedside. It also supports increased
visibility and efficiency for both pharmacy and nursing through the
ability to track medications in transit.
"As an early adopter of the latest
BD Pyxis ES system release, we are excited to see the new
enhancements and innovations come to life," said Bruce Latimer, director of pharmacy at Kingman
Medical Center. "Not only are we experiencing significant
performance enhancements and easy upgrades, we're also very happy
with system interoperability, optimization, user security
improvements and how this new software release will help us adopt
new simpler workflows and continuously help us evolve and improve
medication safety."
End-to-end medication safety:
- BD is extending its IV compounding safety to a much broader set
of IV medications. The new enhancements of the BD Pyxis IV
prep (formerly branded BD Cato™), include even more
configuration options to support hospital and health systems'
operations. BD Pyxis IV prep raises the bar on patient safety,
offering real-time detection of errors for more accurate
preparation of IVs.
In addition to displaying a broad range of enhanced solutions,
join BD in booth 721 to participate in a variety of BD-sponsored
conference activities, including an in-booth speaker theater where
hospitals and health systems will share expertise in medication
management across the care continuum. See the full schedule,
including BD-sponsored CE opportunities, at bd.com/ashp2017.
About BD
BD is a global medical technology company that is advancing
the world of health by improving medical discovery, diagnostics
and the delivery of care. BD leads in patient and health care
worker safety and the technologies that enable medical research and
clinical laboratories. The company provides innovative solutions
that help advance medical research and genomics, enhance the
diagnosis of infectious disease and cancer, improve medication
management, promote infection prevention, equip surgical and
interventional procedures, and support the management of diabetes.
The company partners with organizations around the world to address
some of the most challenging global health issues. BD has nearly
50,000 associates across 50 countries who work in close
collaboration with customers and partners to help enhance outcomes,
lower health care delivery costs, increase efficiencies, improve
health care safety and expand access to health. For more
information on BD, please visit bd.com.
This press release contains certain estimates and other
forward-looking statements (as defined under Federal securities
laws) regarding potential future sales and product development.
Forward looking statements may be identified by use of words such
as "will", "plan", "believe", "expect" or other words of similar
meaning. All such statements are based upon the current
expectations of BD and involve a number of business risks and
uncertainties. Actual results could vary materially from
anticipated results described, implied or projected in any
forward-looking statement. A number of factors could cause actual
results to vary materially, including, without limitation,
difficulties inherent in product development, delays in product
introductions and uncertainty of market acceptance of new products;
competitive factors including technological advances and new
products introduced by competitors; pricing and market pressures;
potential cuts in governmental healthcare spending and measures to
contain healthcare costs; adverse changes in regional, national or
foreign economic conditions; product efficacy or safety concerns;
fluctuations in costs and availability of materials and in BD's
ability to maintain favorable supplier arrangements and
relationships; new or changing laws and regulations impacting our
business or changes in enforcement practices with respect to such
laws; future healthcare reform; as well as other factors discussed
in BD's filings with the Securities and Exchange Commission. We do
not intend to update any forward-looking statements to reflect
events or circumstances after the date hereof except as required by
applicable laws or regulations.
Contacts:
|
|
Matt
Coppola
|
Monique N.
Dolecki
|
BD Public
Relations
|
BD Investor
Relations
|
201.847.7370
|
201.847.5378
|
matthew_r_coppola@bd.com
|
monique_dolecki@bd.com
|
View original
content:http://www.prnewswire.com/news-releases/bd-announces-new-offerings-to-help-customers-deliver-safer-simpler-and-smarter-medication-management-300565653.html
SOURCE BD (Becton, Dickinson and Company)